Akademik Veri Yönetim Sistemi
Anestezi Dergisi, cilt.13, sa.3, ss.205-208, 2005 (Scopus)
At the microcirculation level erythrocyte deformability and plasma viscosity are the main determinants of the resistance against blood flow. The effects of the propofol and some volatile agents on the erythrocyte deformability have been studied previously. Whereas the effect of midazolam on erythrocyte deformability and plasma viscosity has not been studied. The objective of our study was to determine the effects of midazolam on erythrocyte deformability and plasma viscosity. Twenty Wistar albino rats were randomly divided into three groups. The first group was the control group, that did not receive any injection. The second (vehicle group) and third groups (Midazolam group) received intraperitoneal injections at equal volumes of either the solvent of midazolam or 50 mg kg-1 midazolam, respectively. The erythrocyte deformability and plasma viscosity in each of the three groups were similar. The erythrocyte deformability index of the control group was 1,26 ± 0,08 where as it was 1,26 ± 0,2 for the solvent group and 1,28 ± 0,09 for the midazolam group. Plasma viscosity was found 1,53 ± 0,11 in the control group where it was 1,78 ± 0,5 and 1,45 ± 0,2 for the solvent group and midazolam group respectively. Midazolam did not have any effects on these parameters. So, midazolam can be used safely in patients with problems at microcirculation level. These findings might have important clinical implications such as in ischemic brain and heart diseases, intensive care unit sedation of septic shock cases and hyperviscosity syndromes.